This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
User:Kylie Blake/Sandbox 1
From Proteopedia
< User:Kylie Blake(Difference between revisions)
| (39 intermediate revisions not shown.) | |||
| Line 4: | Line 4: | ||
[https://en.wikipedia.org/wiki/Amylin_receptor Amylin Receptor] | [https://en.wikipedia.org/wiki/Amylin_receptor Amylin Receptor] | ||
| + | <ref name="7TYF">PMID:35324283</ref> | ||
== Function == | == Function == | ||
| - | <name='10/1037496/ | + | <scene name='10/1037496/C-term_amide/3'>TextToBeDisplayed</scene> |
| + | <scene name='10/1037496/Overlay_of_ramps/1'>Overlay of RAMPs</scene> | ||
| + | <scene name='10/1037496/Overlay_of_ligands/1'>Overlay of Ligands</scene> | ||
| + | <scene name='10/1037496/G_protein_interaction/1'>Arg 180 and Gln 390 interaction</scene> | ||
| + | <scene name='10/1037496/H2ophobic_interactions/1'>Hydrophobic interactions in G protein activation</scene> | ||
== Disease == | == Disease == | ||
| + | [[Image:bio role.jpg|500 px|right|thumb|Figure number]] | ||
| + | |||
| + | [[Image:Pramlintide.jpeg|500 px|right|thumb|Figure number]] | ||
| + | [[Image:Amylin brain.jpeg|500 px|right|thumb|Figure number]] | ||
| + | |||
| + | [[Image:Overlay of RAMPs.png|500 px|right|thumb|Figure number]] | ||
== Relevance == | == Relevance == | ||
| + | |||
| + | <ref name="Hay">PMID:26071095</ref> | ||
| + | <ref name="Grizzanti">PMID:30282360</ref> | ||
| + | <ref name="Cao">PMID:35324283</ref> | ||
| + | <ref name="Mathiesen">PMID:33488526</ref> | ||
| + | |||
| + | <ref name="Thapa">Thapa, G., Kumari, A., Dasgupta, D., Bandyopadhy, S., Sarkar, N., Roy, K., Karunakaran, G., Kazmi, I., Karmakar, S., & Chakraborty, M. (2023). Chapter 5- Insight into the mechanism of action of anti-diabetic drugs. ''How Synthetic Drugs Work.'' 95-122. [http://dx.doi.org/10.1016/B978-0-323-99855-0.00005-1 DOI:10.1016/B978-0-323-99855-0.00005-1]</ref> | ||
| + | <ref name="Press"> Press, M., Jung, T., Konig, J., Grune, T., & Hohn, A. (2019). Protein aggregates and proteostasis in aging: Amylin and β-cell function. ''Mechanisms of Ageing and Development. 3,'' 46-54. [http://dx.doi.org/10.1016/j.mad.2018.03.010 DOI:10.1016/j.mad.2018.03.010]</ref> | ||
| + | |||
| + | DOI:10.1016/j.mad.2018.03.010 | ||
| + | |||
== Structural highlights == | == Structural highlights == | ||
| - | [[Image: | + | |
| + | <scene name='10/1037494/Transmembrane/4'>Transmembrane</scene> | ||
| + | <scene name='10/1037495/Amylin_disulfide_bond2/1'>TextToBeDisplayed</scene> | ||
| + | |||
| + | [[Image:RAMP_diagram.jpg|400px|right|thumb|Figure 2.]] | ||
</StructureSection> | </StructureSection> | ||
| Line 18: | Line 44: | ||
== References == | == References == | ||
<references/> | <references/> | ||
| + | |||
| + | <ref name="7TYF"/> | ||
| + | <ref name="Hay"> | ||
| + | <ref name="Grizzanti"> | ||
| + | <ref name="Cao"> | ||
| + | <ref name="Mathiesen"> | ||
| + | <ref name="Thapa"> | ||
| + | <ref name="Press"> | ||
| + | |||
==Student Contributors== | ==Student Contributors== | ||
Current revision
Amylin Receptor, AMYr, Protein
| |||||||||||
References
- ↑ Cao J, Belousoff MJ, Liang YL, Johnson RM, Josephs TM, Fletcher MM, Christopoulos A, Hay DL, Danev R, Wootten D, Sexton PM. A structural basis for amylin receptor phenotype. Science. 2022 Mar 25;375(6587):eabm9609. PMID:35324283 doi:10.1126/science.abm9609
- ↑ Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: Pharmacology, Physiology, and Clinical Potential. Pharmacol Rev. 2015 Jul;67(3):564-600. PMID:26071095 doi:10.1124/pr.115.010629
- ↑ Grizzanti J, Corrigan R, Casadesus G. Neuroprotective Effects of Amylin Analogues on Alzheimer's Disease Pathogenesis and Cognition. J Alzheimers Dis. 2018;66(1):11-23. PMID:30282360 doi:10.3233/JAD-180433
- ↑ Cao J, Belousoff MJ, Liang YL, Johnson RM, Josephs TM, Fletcher MM, Christopoulos A, Hay DL, Danev R, Wootten D, Sexton PM. A structural basis for amylin receptor phenotype. Science. 2022 Mar 25;375(6587):eabm9609. PMID:35324283 doi:10.1126/science.abm9609
- ↑ Mathiesen DS, Lund A, Vilsbøll T, Knop FK, Bagger JI. Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. Front Endocrinol (Lausanne). 2021 Jan 8;11:617400. PMID:33488526 doi:10.3389/fendo.2020.617400
- ↑ Thapa, G., Kumari, A., Dasgupta, D., Bandyopadhy, S., Sarkar, N., Roy, K., Karunakaran, G., Kazmi, I., Karmakar, S., & Chakraborty, M. (2023). Chapter 5- Insight into the mechanism of action of anti-diabetic drugs. How Synthetic Drugs Work. 95-122. DOI:10.1016/B978-0-323-99855-0.00005-1
- ↑ Press, M., Jung, T., Konig, J., Grune, T., & Hohn, A. (2019). Protein aggregates and proteostasis in aging: Amylin and β-cell function. Mechanisms of Ageing and Development. 3, 46-54. DOI:10.1016/j.mad.2018.03.010
